Pleased to see several research findings recently published from our @CEPIvaccines funded RCTs of COVID-19 booster vaccination in Australia (Melbourne) and Mongolia:
10.1016/j.jinf.2026.106727
10.1016/j.vaccine.2026.128574
10.3389/fimmu.2026.1789248
10.3389/fimmu.2026.1779435
These publications report on:
1. 12-month followup of our Melb RCT
2. Time-of-Day vaccine effect on immunogenicity
3. 24-month followup of our Mongolia RCT of fractional v standard mRNA dosing
4. 12-month followup of CMI response in Mongolian RCT
Important for booster strategies
A massive thanks to everyone involved including all study participants!
@LicciardiLab @NadiaMazarakis @ZhengQToh Rachel Higgins Claire von Mollendorf @MulhollandKim @darrens_ong @LienAnhHaDo1 @TsegiBatmunkh and everyone else
@MCRI_for_kids NCCD Mongolia
LicciardiLab retweeted
Half the funding. Half the future.
The Medical Research Future Fund was meant to deliver $1B each year — only $650M is reaching researchers.
Join the call to release the full funds now.
aamri.org.au/mrff
#releasethefullmrff
@Mark_Butler_MP @JEChalmers
LicciardiLab retweeted
How multidisciplinary scientists & policy makers can work together to translate new knowledge into policy using a learning health systems approach
Our 2nd Forum
On PCV Access and Sustainability hosted by our @nhmrc Centre for Research Excelkence
mcri.edu.au/news/events/asia…
LicciardiLab retweeted
In 2024, nearly 38 million children under five were acutely malnourished across 26 nutrition crises.
“We cannot respond to empty stomachs with empty hands and turned backs.” - @antonioguterres
Learn more. ⬇️
LicciardiLab retweeted
One dose of the human papillomavirus (HPV) #vaccine is just as effective in providing long-term immune protection against #cervicalcancer as a two or three dose schedule, a new #MCRI-led study finds. 👉 nature.com/articles/s41467-0…
@LicciardiLab @ZhengQToh @qChauQuang
LicciardiLab retweeted
MCRI's Dr Nadia Mazarakis said both vaccines produced similar T-cell responses (a key part of your immune system that protects you from harmful viruses). The findings could help inform ongoing #booster strategies.
LicciardiLab retweeted
A new MCRI study found that as a 4th dose, Moderna boosted more #antibodies than Novavax but also caused more side effects. However, both #vaccines activated the immune system in a similar way.
Read more ➡️ doi.org/10.1016/j.jinf.2025.…
@CEPIvaccines
ALT Image of a little girl getting her vaccination.
Our latest research on single dose #HPV vaccination just published @NatureComms -supports one dose strategy using systems serology rdcu.be/eb1cs
Great team science @ZhengQToh @AmyWChung and our PhD student @qChauQuang and everyone else involved @MCRI_for_kids @UniMelb
LicciardiLab retweeted
In an unprecedented move, research-grant reviews have been suspended indefinitely at the world’s largest public funder of biomedical research
go.nature.com/4gclXG0
LicciardiLab retweeted
Respiratory syncytial virus (RSV) is a major cause of illness and death in infants and older adults.
A Review in @TheLancetInfDis discusses the different RSV vaccines available and emphasizes the need to ensure these vaccines reach the most vulnerable: hubs.li/Q030TKl10
ALT Overview of RSV vaccine candidates by preventive approach. Copyright: Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
LicciardiLab retweeted
Our @nhmrc CRE developed a new collaboration with @SirirajMedicine Thailand
Our 2 vs 3 PCV dose noninferiority RCT using the more affordable @SerumInstIndia has recruited 100 in 3w 🎉
@LicciardiLab
@CSatzke
@MCRI_for_kids
LicciardiLab retweeted
A new #MCRI led study has found that fewer doses of #pneumococcal vaccines were just as effective at providing sustained immunity among Vietnamese babies. @MenziesResearch @darrens_ong @LicciardiLab @ThanhPh32823293 @ZhengQToh @MulhollandKim
👉 nature.com/articles/s41467-0…
Our recent preprint by postdoc Nadia Mazarakis is out on evaluation of SARS-CoV-2 antibody responses in adults and children using a novel microsampling device doi.org/10.1101/2024.07.24.2… Great to have the collaboration with @trajanscimed @SynexaLS @MCRI_for_kids @ZhengQToh
LicciardiLab retweeted
The Melbourne Vaccine Education Centre is inviting healthcare professionals to join an upcoming clinical vaccinology update on RSV at @RCHMelbourne on June 21. | #MCRI #RSV #Vaccination #InfectiousDisease @MVECau
Register ➡️ mvec.mcri.edu.au/events/cvu-…
LicciardiLab retweeted
Now hiring to a project officer role for the PROPHECY study. Large MRFF funded clinical and scientific collaboration studying COVID vaccine responses in high risk populations.@PROPHEC19
livehire.com/job/alfredhealt…
monash.edu/medicine/prophecy…
LicciardiLab retweeted
MCRI's @DanielPellicci has been awarded a Viertel Senior Medical Research Fellowship. This #research could help reduce the severity of #Tuberculosis, #StrepA and #RSV - and pave the way for future #vaccines.
Read more👉mcri.edu.au/news/awards/fell…
ALT Petri dish with micro bacterias and microorganisms
LicciardiLab retweeted
Is the Novavax COVID Vaccine Better than mRNA Vaccines? What We Know So Far - Scientific American scientificamerican.com/artic…
LicciardiLab retweeted
Excited to share this work, led by @sam_manna3 with @markushilty,
Joel & Neil, together with
@stephlo_lo @LicciardiLab @BelindaOrtika @Eliza__Nikolaou
@Fiona_M_Russell @MulhollandKim @emd3737 & many more not on twitterX especially our colleagues Drs Odgerel & Tuya #Mongolia
This Post is from an account that no longer exists. Learn more